Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 21

Sort by

Sort Order Select

Journal Articles

CD25^high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Cancer Res (2023) 83 (18): 3026–3044.

https://doi.org/10.1158/0008-5472.CAN-23-0613

Published: 15 September 2023

View article titled, CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract CT179: First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)

Johann de Bono, Stéphane Champiat, Francois-Xavier Danlos, Martin Wermke, Volker Kunzmann, Aude De Gassart, Emmanuel Valentin, Marina Iche, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Aurélien Marabelle, Daniel Olive, Paul Frohna

Cancer Res (2023) 83 (8_Supplement): CT179.

https://doi.org/10.1158/1538-7445.AM2023-CT179

Published: 14 April 2023

View article titled, Abstract CT179: First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)

Journal Articles

Abstract 3239: Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers

Cancer Res (2023) 83 (7_Supplement): 3239.

https://doi.org/10.1158/1538-7445.AM2023-3239

Published: 04 April 2023

View article titled, Abstract 3239: Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers

Journal Articles

Abstract 710: Preclinical development of ALD2510, a Next-Gen Fc-enhanced, T_REG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors

Jemila Houacine, Riad Abes, Anne Marie-Cardine, Aude Le Roy, Bettina Serbin, Lucie Robert, Jérôme Giustiniani, Anne-Sophie Chrétien, Stéphane Fattori, Laurent Gorvel, Armand Bensussan, Daniel Olive, Arnaud Foussat

Cancer Res (2023) 83 (7_Supplement): 710.

https://doi.org/10.1158/1538-7445.AM2023-710

Published: 04 April 2023

View article titled, Abstract 710: Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors

Journal Articles

Abstract 5184: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Laurent GORVEL, Clemence Demerle, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Fabien Angelis, Frederic Fiore, Jacques Nunes, Bernard Malissen, Laurent Greillier, Geoffrey Guittard, Herve Luche, Fabrice Barlesi, Daniel Olive

Cancer Res (2023) 83 (7_Supplement): 5184.

https://doi.org/10.1158/1538-7445.AM2023-5184

Published: 04 April 2023

View article titled, Abstract 5184: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Journal Articles

Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer

Stephane Fattori, Hugo Roux, Emilie Connen, Lucie Robert, Laurent Gorvel, Aude Le Roy, Jemila Houacine, Arnaud Foussat, Anne-Sophie Chretien, Daniel Olive

Cancer Res (2022) 82 (21): 3868–3879.

https://doi.org/10.1158/0008-5472.CAN-22-0654

Published: 02 November 2022

View article titled, Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer

Journal Articles

Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

Cancer Res (2022) 82 (12_Supplement): CT188.

https://doi.org/10.1158/1538-7445.AM2022-CT188

Published: 15 June 2022

View article titled, Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

Journal Articles

Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Cancer Res (2022) 82 (8): 1671.

https://doi.org/10.1158/0008-5472.CAN-22-0500

Published: 15 April 2022

View article titled, Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Journal Articles

Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

Aurelien Marabelle, Christiane Jungels, Johann De Bono, Norbert Vey, Martin Wermke, Elena Garralda, Steven Le Gouill, Patricia LoRusso, Aude De Gassart, Emmanuel Valentin, Patrick Brune, Marina Iche, Daniel Olive, Paul A. Frohna

Cancer Res (2021) 81 (13_Supplement): CT034.

https://doi.org/10.1158/1538-7445.AM2021-CT034

Published: 01 July 2021

View article titled, Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

Journal Articles

Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy

Kieu-Suong Le, Marie-Laure Thibult, Sylvain Just-Landi, Sonia Pastor, Françoise Gondois-Rey, Samuel Granjeaud, Florence Broussais, Reda Bouabdallah, Renaud Colisson, Christophe Caux, Christine Ménétrier-Caux, Dominique Leroux, Luc Xerri, Daniel Olive

Cancer Res (2016) 76 (16): 4648–4660.

https://doi.org/10.1158/0008-5472.CAN-15-0589

Published: 14 August 2016

View article titled, Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy

Includes: Supplementary data

Journal Articles

Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity

Christine Pasero, Gwenaëlle Gravis, Mathilde Guerin, Samuel Granjeaud, Jeanne Thomassin-Piana, Palma Rocchi, Maria Paciencia-Gros, Flora Poizat, Mélanie Bentobji, Francine Azario-Cheillan, Jochen Walz, Naji Salem, Serge Brunelle, Alessandro Moretta, Daniel Olive

Cancer Res (2016) 76 (8): 2153–2165.

https://doi.org/10.1158/0008-5472.CAN-15-1965

Published: 14 April 2016

View article titled, Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity

Includes: Supplementary data

Journal Articles

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies

Sandra Heskamp, Willemijn Hobo, Janneke D.M. Molkenboer-Kuenen, Daniel Olive, Wim J.G. Oyen, Harry Dolstra, Otto C. Boerman

Cancer Res (2015) 75 (14): 2928–2936.

https://doi.org/10.1158/0008-5472.CAN-14-3477

Published: 14 July 2015

View article titled, Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies

Journal Articles

ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Cancer Res (2014) 74 (23): 6820–6832.

https://doi.org/10.1158/0008-5472.CAN-14-0303

Published: 30 November 2014

View article titled, ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Includes: Multimedia, Supplementary data

Journal Articles

PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

Cancer Res (2013) 73 (1): 128–138.

https://doi.org/10.1158/0008-5472.CAN-12-2606

Published: 02 January 2013

View article titled, PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

Includes: Supplementary data

Journal Articles

ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4⁺ T Cells

Julien Faget, Nathalie Bendriss-Vermare, Michael Gobert, Isabelle Durand, Daniel Olive, Cathy Biota, Thomas Bachelot, Isabelle Treilleux, Sophie Goddard-Leon, Emilie Lavergne, Sylvie Chabaud, Jean Yves Blay, Christophe Caux, Christine Ménétrier-Caux

Cancer Res (2012) 72 (23): 6130–6141.

https://doi.org/10.1158/0008-5472.CAN-12-2409

Published: 29 November 2012

View article titled, ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells

Includes: Supplementary data

Journal Articles

Abstract 5402: Functionally altered plasmacytoid DC in breast tumor environment play a central role in Treg and Tr1-like expansion through ICOS engagement

Julien Faget, Nathalie Bendriss-Vermare, Thomas Bachelot, Vanja Sisirak, Mickael Gobert, Isabelle Durand, Catherine Biota, Isabelle Treilleux, Sophie Goddard-Léon, Jean-Yves Blay, Daniel Olive, Christophe Caux, Christine Ménétrier-Caux

Cancer Res (2012) 72 (8_Supplement): 5402.

https://doi.org/10.1158/1538-7445.AM2012-5402

Published: 15 April 2012

View article titled, Abstract 5402: Functionally altered plasmacytoid DC in breast tumor environment play a central role in Treg and Tr1-like expansion through ICOS engagement

Journal Articles

Abstract 5407: The upregulation of BTLA and PD-1 defines a novel subset of dysfunctional tumor antigen-specific CD8+ T cells

Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Philippe Guillaume, Immanuel F. Luescher, Cindy Sander, John M. Kirkwood, Daniel Olive, Vijay Kuchroo, Hassane M. Zarour

Cancer Res (2012) 72 (8_Supplement): 5407.

https://doi.org/10.1158/1538-7445.AM2012-5407

Published: 15 April 2012

View article titled, Abstract 5407: The upregulation of BTLA and PD-1 defines a novel subset of dysfunctional tumor antigen-specific CD8+ T cells

Journal Articles

CD8⁺ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Julien Fourcade, Zhaojun Sun, Ornella Pagliano, Philippe Guillaume, Immanuel F. Luescher, Cindy Sander, John M. Kirkwood, Daniel Olive, Vijay Kuchroo, Hassane M. Zarour

Cancer Res (2012) 72 (4): 887–896.

https://doi.org/10.1158/0008-5472.CAN-11-2637

Published: 14 February 2012

View article titled, CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Includes: Supplementary data

Journal Articles

Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition

Emilie Mamessier, Aude Sylvain, François Bertucci, Rémy Castellano, Pascal Finetti, Gilles Houvenaeghel, Emmanuelle Charaffe-Jaufret, Daniel Birnbaum, Alessandro Moretta, Daniel Olive

Cancer Res (2011) 71 (21): 6621–6632.

https://doi.org/10.1158/0008-5472.CAN-11-0792

Published: 30 October 2011

View article titled, Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition

Includes: Supplementary data

Journal Articles

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

Michael Gobert, Isabelle Treilleux, Nathalie Bendriss-Vermare, Thomas Bachelot, Sophie Goddard-Leon, Vanessa Arfi, Cathy Biota, Anne Claire Doffin, Isabelle Durand, Daniel Olive, Solène Perez, Nicolas Pasqual, Christelle Faure, Isabelle Ray-Coquard, Alain Puisieux, Christophe Caux, Jean-Yves Blay, Christine Ménétrier-Caux

Cancer Res (2009) 69 (5): 2000–2009.

https://doi.org/10.1158/0008-5472.CAN-08-2360

Published: 02 March 2009

View article titled, Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

Includes: Supplementary data

NARROW

CD25^high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Abstract CT179: First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)

Abstract 3239: Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers

Abstract 710: Preclinical development of ALD2510, a Next-Gen Fc-enhanced, T_REG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors

Abstract 5184: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer

Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial

Editor's Note: ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy

Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies

ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4⁺ T Cells

Abstract 5402: Functionally altered plasmacytoid DC in breast tumor environment play a central role in Treg and Tr1-like expansion through ICOS engagement

Abstract 5407: The upregulation of BTLA and PD-1 defines a novel subset of dysfunctional tumor antigen-specific CD8+ T cells

CD8⁺ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only